Using a special part of antibodies for better drug delivery and imaging
Exploiting the Hydrophobic Glycosyl Pocket of IgG1 for Imaging and Drug Delivery Applications
This study is exploring a new way to attach drugs to antibodies, which could help treat cancer and autoimmune diseases more effectively, by using a special part of the antibody that protects the drugs from breaking down in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of Ny,binghamton NIH-funded |
| Lab location | 1 site (Binghamton, United States) |
| Project ID | NIH-10842244 on NIH RePORTER |
What this research studies
This research focuses on improving how antibodies can deliver drugs and help with imaging by using a specific site on the antibody that is well-protected from enzymes in the body. The project aims to develop techniques that allow for the attachment of large, nonpolar drug molecules to this site without needing complex engineering of the antibodies. By understanding the unique properties of this site, researchers hope to create more effective antibody-drug conjugates for treating conditions like cancer and autoimmune diseases. The work involves optimizing the linkers that connect the drug to the antibody to ensure effective delivery.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer or autoimmune diseases who may benefit from advanced antibody-mediated therapies.
Not a fit: Patients who do not have cancer or autoimmune diseases may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cancer and autoimmune diseases through improved drug delivery methods.
How similar studies have performed: Other research has shown promise in using antibody-mediated drug delivery, but this specific approach is relatively novel and has not been extensively tested.
Where this research is happening
Binghamton, United States
- State University of Ny,binghamton — Binghamton, United States (Active)
Researchers
- Principal investigator: Tumey, Lawrence — State University of Ny,binghamton
- Study coordinator: Tumey, Lawrence
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.